Overall, our findings elucidated that TRIM22 acted as an E3 ligase targeting p21 for degradation to promote melanoma progression, which improved the understanding of TRIM22 function and provided more clues for developing TRIM22 as a potential target for malignant melanoma treatment. Here, CDKN1A is linked to melanoma.